Antibody Based Therapy to Treat Cancer and GI Related Diseases

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

A novel therapeutic antibody against MMP-7, with exceptional specificity, for the treatment of aggressive cancers. Although early programs targeting MMPs (matrix metalloproteins) were largely unsuccessful due to adverse side effects, they remain a viable and highly desirable therapeutic target. The main obstacle in the attempts to target MMPs is the ability to selectively target individual MMPs. The present invention provides highly selective targeted therapy against MMP-7, which is strongly associated with aspects of cancer development such as angiogenesis and metastasis.
In a further development of their previous groundbreaking synthetic metal-protein mimicry molecules, researchers from Prof. Irit Sagi’s lab generated an antibody which exhibits exceptional degree of specificity towards MMP-7 over other MMPs. The present technology offers an opportunity to re-introduce improved MMP-targeting agents to the cancer therapeutics market, in particular aggressive cancers that face a major unmet medical need.


Background and Unmet Need

Matrix metalloproteins (MMPs), a family of zinc-dependent endopeptidases, are key enzymes participating in remodeling of the extracellular matrix (ECM), and are thus critical for processes such as vascularization and cell migration. Imbalanced activity of MMPs may result in a variety of physiological and pathological processes, predominantly cancer, affecting angiogenesis, tumor growth and metastasis (Figure 1). Accordingly, MMP expression is tied to tumor aggressiveness, stage, and patient prognosis. MMP-7 (also known as Matrilysin, PUMP-1, or uterine metalloproteinase) has been particularly associated with malignat tumors and is considered to have an important role in tumor invasion and metastasis. Owing to this role are specific expression in epithelial tissues and a broad range of substrates including Collagen IV and X, Caesin, Laminin, Elastin and other members of the MMP family. Among the cancer types in which MMP-7 was implicated, are esophagus, stomach, colon, liver, pancreas, ovarian and renal cell carcinomas.
Several attempts to take advantage of the great therapeutic potential of targeting MMPs failed due to severe toxicities. The basis for this toxicity was found to be poor selectivity towards specific MMPs. It is now recognized that among MMPs, some possess cancer-promoting activities while others tumor-inhibiting functions, underlining the risk of using broad-spectrum MMP inhibitors.
There is therefore a need to re-introduce MMP-targeting (and MMP-7 in particular) programs back to the cancer market. Such therapeutics must offer high selectivity while maintaining the promising therapeutic potential of


Figure 1: MMPs can facilitate tumor cell metastasis and angiogenesis.

The Solution

The present invention provides a highly selective inhibitory antibody against MMP-7.
The innovative concept leading to this high selectivity is immunization with both a synthetic metal-protein mimicry molecule, previously developed by the present inventors, followed by the metalloenzyme itself (e.g., MMP-7). The specificity of the resulting antibody (as defined by Ki) is measured to be at least 5-fold higher towards MMP-7 than towards other MMPs.

Technology Essence

The present technology is based on a previous invention that was developed in Prof. Sagi's lab, of synthetic metalprotein mimicry molecules that mimic the conserved structure of the metalloenzyme catalytic zinc-histidine complex within the active site of each MMP enzyme.
These molecules were shown to be powerful immunogens in the generation of highly selective MMP antibodies since they recognize both electrical and structural determinants residing within the enzyme active site. The potential of this method to successfully generate MMP-targeting therapeutics was shown for MMP-9/2 inhibitory antibodies in mouse models of inflammatory bowel disease[1].
Sagi and her team now take this invention a step further to achieve even higher specificity. They show that immunizing with the mimicking molecules described above, followed by immunization with the metalloenzyme itself increases selectivity further.
Implemented for MMP-7-targeting, this approach yielded an antibody with a 5-fold lower Ki towards MMP-7 than towards other MMPs (e.g., MMp-2 and MMP-9).

Applications and Advantages

  • Therapy for MMP-7 associated diseases
  • Diagnostic tool for MMP-7 associated diseases
  • Highly selective - avoids adverse effects that were associated with broad spectrum MMP inhibitors.
  • Efficient – targeting a physiological active conformation of the enzyme


[1] Sela-Passwell N [1].et al., Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med. [2] 2011. 18(1):143-7.

Intellectual property status

  • Granted Patent
  • Patent application number :European Patent Office Published: Publication Number: 3920965 USA Granted: 10,066,024

Related Keywords

  • Biological Sciences
  • Medical Research
  • Biology / Biotechnology
  • Micro- and Nanotechnology related to Biological sciences
  • Genetic Engineering / Molecular Biology
  • Pharmaceuticals/fine chemicals

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support